Scoping to analyze oncology trial participation in Australia.
Semin Oncol
; 49(2): 178-181, 2022 04.
Article
de En
| MEDLINE
| ID: mdl-35595552
ABSTRACT
Equity in oncology clinical trial participation has been declared a global priority. Australia is a key stakeholder in the global clinical trials sphere and managed to maintain high clinical trial activity during the COVID pandemic. Despite these successes, there is paucity of understanding about what influences clinical trial participation in Australia. In the international context, systematic reviews have highlighted that sociodemographic barriers, access to health care, clinical trial inclusion criteria, and attitudes of physicians and patients are factors which influence oncology trial participation. Exploring the factors in Australian health services which influence trial participation is now of significant importance. The lack of clear evidence directly highlights a need to assess the factors that influence oncology trial participation in Australia. We call for review of existing data to identify future directions in Australia which will potentially give deeper insights for the international clinical trial community.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Médecins
/
COVID-19
/
Tumeurs
Type d'étude:
Prognostic_studies
Limites:
Humans
Pays/Région comme sujet:
Oceania
Langue:
En
Journal:
Semin Oncol
Année:
2022
Type de document:
Article